Check Out What’s New at Goldfinch

Filter by year:

11.19.20

Goldfinch Bio Announces Appointment of Robin A. Walker, J.D., as Chief Legal Officer

10.22.20

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

10.14.20

Goldfinch Bio Honored by Goldman Sachs for Entrepreneurship

10.13.20

Goldfinch Bio Announces Upcoming Presentation of Phase 1 Clinical Data for Lead Precision Kidney Therapeutic Candidate, GFB-887, and Expansion of Scientific Leadership Team

10.07.20

Academic and Industry Collaborative Study, including Goldfinch Bio, Demonstrates Benefit of Proteinuria Reduction on Kidney Survival in Patients with Focal Segmental Glomerulosclerosis (FSGS)

Our goal with The Feeder is to create an enriching source of information. Each month we will feature a new conversation with a range of people – from those living with kidney disease and researchers pioneering new scientific frontiers to advocacy leaders driving change and Goldfinch Bio scientists advancing precision kidney medicines. With this collection of diverse perspectives, we aim to shed light on the unmet need and the tremendous opportunity to bring hope and renewed quality of life to people living with kidney diseases.

February 2021

As part of our interview series, “The Feeder,” Jill H., who was diagnosed with focal segmental glomerulosclerosis, or FSGS, at age 14 speaks with our President & CEO Tony Johnson, M.D., about living with and managing this disease, including her experience with dialysis and kidney transplants.